Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$27.62
1.043.91%
al cierre: -
$27.10
-0.52-1.88%
After hour: 4:57 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Apellis Pharmaceuticals Inc ha un obiettivo di prezzo di consenso pari a $41.68, stabilito in base alle ultime valutazioni degli analisti di 23. Le ultime 3 valutazioni degli analisti sono state rilasciate da JP Morgan, Citigroup y RBC Capital il agosto 4, 2025, agosto 1, 2025 y agosto 1, 2025. Con un obiettivo di prezzo medio di $36 tra le JP Morgan, Citigroup y RBC Capital, c'è un implicito 32.84% upside per Apellis Pharmaceuticals Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
JP Morgan
Citigroup
RBC Capital
Cantor Fitzgerald
Raymond James
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Apellis Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/04/2025 | 36.53% | JP Morgan | $35 → $37 | Maintains | Overweight | |||
08/01/2025 | 91.88% | Citigroup | $46 → $52 | Maintains | Buy | |||
08/01/2025 | -29.89% | RBC Capital | $17 → $19 | Maintains | Sector Perform | |||
08/01/2025 | 47.6% | Cantor Fitzgerald | $39 → $40 | Maintains | Overweight | |||
08/01/2025 | 84.5% | Raymond James | $52 → $50 | Maintains | Outperform | |||
07/29/2025 | 69.74% | Citigroup | $41 → $46 | Maintains | Buy | |||
07/18/2025 | 84.5% | Baird | $47 → $50 | Maintains | Outperform | |||
07/16/2025 | -11.44% | B of A Securities | $23 → $24 | Maintains | Neutral | |||
07/02/2025 | -4.06% | Morgan Stanley | $25 → $26 | Maintains | Equal-Weight | |||
06/02/2025 | 7.01% | Wells Fargo | $26 → $29 | Maintains | Equal-Weight | |||
05/22/2025 | 51.29% | Citigroup | $49 → $41 | Maintains | Buy | |||
05/14/2025 | -26.2% | Mizuho | $30 → $20 | Maintains | Neutral | |||
05/09/2025 | 91.88% | Raymond James | $75 → $52 | Downgrade | Strong Buy → Outperform | |||
05/09/2025 | -15.13% | B of A Securities | $41 → $23 | Downgrade | Buy → Neutral | |||
05/08/2025 | -33.58% | RBC Capital | $21 → $18 | Maintains | Sector Perform | |||
05/08/2025 | -26.2% | Scotiabank | $28 → $20 | Maintains | Sector Perform | |||
05/08/2025 | -4.06% | Wells Fargo | $30 → $26 | Maintains | Equal-Weight | |||
05/08/2025 | 73.43% | Baird | $55 → $47 | Maintains | Outperform | |||
05/07/2025 | 7.01% | Needham | $40 → $29 | Maintains | Buy | |||
04/29/2025 | 62.36% | Cantor Fitzgerald | → $44 | Initiates | → Overweight | |||
04/21/2025 | -22.51% | RBC Capital | $24 → $21 | Maintains | Sector Perform | |||
04/02/2025 | 14.39% | Scotiabank | $30 → $31 | Maintains | Sector Perform | |||
03/04/2025 | 99.26% | JP Morgan | $50 → $54 | Maintains | Overweight | |||
03/03/2025 | -7.75% | RBC Capital | $26 → $25 | Maintains | Sector Perform | |||
03/03/2025 | 18.08% | Goldman Sachs | $36 → $32 | Maintains | Neutral | |||
03/03/2025 | 7.01% | Wedbush | $30 → $29 | Maintains | Neutral | |||
03/03/2025 | 110.33% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
02/13/2025 | 110.33% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
01/29/2025 | -4.06% | RBC Capital | $26 → $26 | Maintains | Sector Perform | |||
01/21/2025 | -4.06% | RBC Capital | $26 → $26 | Reiterates | Sector Perform → Sector Perform | |||
01/14/2025 | 110.33% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
12/17/2024 | 32.84% | Goldman Sachs | → $36 | Downgrade | Buy → Neutral | |||
11/21/2024 | 14.39% | Morgan Stanley | → $31 | Initiates | → Equal-Weight | |||
11/07/2024 | 102.95% | Baird | $92 → $55 | Maintains | Outperform | |||
11/06/2024 | 88.19% | Citigroup | $63 → $51 | Maintains | Buy | |||
11/06/2024 | 32.84% | Goldman Sachs | $71 → $36 | Maintains | Buy | |||
11/06/2024 | -11.44% | RBC Capital | $25 → $24 | Maintains | Sector Perform | |||
11/06/2024 | 10.7% | Scotiabank | $35 → $30 | Maintains | Sector Perform | |||
11/06/2024 | 10.7% | Wells Fargo | $43 → $30 | Maintains | Equal-Weight | |||
11/06/2024 | 47.6% | Oppenheimer | $65 → $40 | Maintains | Outperform | |||
11/06/2024 | 18.08% | Piper Sandler | $40 → $32 | Maintains | Neutral | |||
11/06/2024 | 110.33% | HC Wainwright & Co. | $83 → $57 | Maintains | Buy | |||
11/06/2024 | 73.43% | B of A Securities | $61 → $47 | Maintains | Buy | |||
11/06/2024 | 121.4% | Needham | $85 → $60 | Maintains | Buy | |||
11/04/2024 | -7.75% | RBC Capital | $25 → $25 | Reiterates | Sector Perform → Sector Perform | |||
10/24/2024 | 40.22% | Mizuho | $39 → $38 | Maintains | Neutral | |||
10/16/2024 | 29.15% | Scotiabank | → $35 | Initiates | → Sector Perform | |||
10/16/2024 | — | William Blair | — | Initiates | → Outperform | |||
09/24/2024 | 58.67% | Wells Fargo | $47 → $43 | Maintains | Equal-Weight | |||
09/23/2024 | 239.48% | Baird | $96 → $92 | Maintains | Outperform | |||
09/20/2024 | 43.91% | Mizuho | $42 → $39 | Maintains | Neutral | |||
09/20/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
09/13/2024 | 110.33% | JP Morgan | $64 → $57 | Maintains | Overweight | |||
08/13/2024 | 136.16% | JP Morgan | $72 → $64 | Maintains | Overweight | |||
08/09/2024 | 206.27% | UBS | $85 → $83 | Maintains | Buy | |||
08/09/2024 | 51.29% | Wedbush | $38 → $41 | Maintains | Neutral | |||
08/09/2024 | 173.06% | Goldman Sachs | $66 → $74 | Maintains | Buy | |||
08/09/2024 | 254.24% | Baird | $86 → $96 | Maintains | Outperform | |||
08/09/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
08/02/2024 | 206.27% | HC Wainwright & Co. | $92 → $83 | Maintains | Buy | |||
08/02/2024 | 143.54% | Goldman Sachs | $77 → $66 | Maintains | Buy | |||
08/02/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
07/31/2024 | 195.2% | Jefferies | $80 → $80 | Maintains | Buy | |||
07/26/2024 | 217.34% | Baird | $100 → $86 | Maintains | Outperform | |||
07/23/2024 | 269% | Baird | $100 → $100 | Maintains | Outperform | |||
07/17/2024 | 184.13% | Goldman Sachs | $90 → $77 | Maintains | Buy | |||
06/28/2024 | 269% | Baird | $100 → $100 | Maintains | Outperform | |||
05/31/2024 | 69.74% | Piper Sandler | → $46 | Initiates | → Neutral | |||
05/28/2024 | 239.48% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
05/23/2024 | 77.12% | Wells Fargo | $57 → $48 | Maintains | Equal-Weight | |||
05/08/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
05/08/2024 | 121.4% | Citigroup | $67 → $60 | Maintains | Buy | |||
05/08/2024 | 239.48% | HC Wainwright & Co. | → $92 | Reiterates | Buy → Buy | |||
05/08/2024 | 213.65% | UBS | $89 → $85 | Maintains | Buy | |||
04/29/2024 | 91.88% | Mizuho | $60 → $52 | Maintains | Neutral | |||
04/26/2024 | 239.48% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
04/25/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
04/17/2024 | 110.33% | Wedbush | $67 → $57 | Maintains | Neutral | |||
04/15/2024 | 239.48% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
04/09/2024 | 213.65% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
03/27/2024 | 121.4% | Mizuho | $60 → $60 | Maintains | Neutral | |||
03/06/2024 | 191.51% | JP Morgan | $78 → $79 | Maintains | Overweight | |||
03/04/2024 | 228.41% | UBS | $87 → $89 | Maintains | Buy | |||
02/28/2024 | 239.48% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
02/28/2024 | 147.23% | Wedbush | $60 → $67 | Maintains | Neutral | |||
02/16/2024 | 121.4% | Mizuho | $49 → $60 | Maintains | Neutral | |||
02/06/2024 | 198.89% | Baird | → $81 | Reiterates | Outperform → Outperform | |||
02/05/2024 | 195.2% | Jefferies | $68 → $80 | Upgrade | Hold → Buy | |||
01/30/2024 | 191.51% | Oppenheimer | $75 → $79 | Maintains | Outperform | |||
01/24/2024 | 176.75% | Needham | $70 → $75 | Maintains | Buy | |||
01/17/2024 | 198.89% | Baird | $71 → $81 | Maintains | Outperform | |||
01/17/2024 | 239.48% | HC Wainwright & Co. | $82 → $92 | Maintains | Buy | |||
01/12/2024 | 121.4% | Wedbush | $39 → $60 | Maintains | Neutral | |||
01/11/2024 | 291.14% | Raymond James | $67 → $106 | Maintains | Strong Buy | |||
01/09/2024 | 232.1% | Goldman Sachs | $65 → $90 | Maintains | Buy | |||
12/15/2023 | 147.23% | Citigroup | $70 → $67 | Maintains | Buy | |||
12/15/2023 | 176.75% | Oppenheimer | $88 → $75 | Maintains | Outperform | |||
12/15/2023 | 147.23% | Raymond James | $93 → $67 | Maintains | Strong Buy | |||
12/14/2023 | 106.64% | Needham | $63 → $56 | Maintains | Buy | |||
12/14/2023 | 99.26% | Wells Fargo | $67 → $54 | Downgrade | Overweight → Equal-Weight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Apellis Pharmaceuticals (APLS)?
El último precio objetivo de Apellis Pharmaceuticals (NASDAQ:APLS) fue comunicado por JP Morgan el agosto 4, 2025. La firma de analistas fijó un precio objetivo para $37.00 que espera APLS a rise dentro de 12 meses (un posible 36.53% upside). 53 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Apellis Pharmaceuticals (APLS)?
La última calificación de analistas para Apellis Pharmaceuticals (NASDAQ:APLS) fue proporcionada por JP Morgan, y Apellis Pharmaceuticals mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Apellis Pharmaceuticals (APLS)?
La última revisión al alza de Apellis Pharmaceuticals Inc se produjo en febrero 5, 2024, cuando Jefferies elevó su precio objetivo a $80. Jefferies anteriormente tenía a hold para Apellis Pharmaceuticals Inc.
¿Cuándo fue la última revisión a la baja de Apellis Pharmaceuticals (APLS)?
La última revisión a la baja de Apellis Pharmaceuticals Inc se produjo en mayo 9, 2025, cuando Raymond James cambió su precio objetivo de $75 a $52 para Apellis Pharmaceuticals Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Apellis Pharmaceuticals (APLS)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Apellis Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Apellis Pharmaceuticals se registró el agosto 4, 2025, por lo que la próxima calificación estará disponible en torno al agosto 4, 2026.
¿Es correcta la calificación de los analistas sobre Apellis Pharmaceuticals (APLS)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Apellis Pharmaceuticals (APLS) fue un mantuvo con un precio objetivo de $35.00 a $37.00. El precio actual al que cotiza Apellis Pharmaceuticals (APLS) es de $27.10, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.